Biliary Excretion of Imatinib and Its Active Metabolite CGP74588 During Severe Hepatic Dysfunction

Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes

(2010) Noelia Nebot et al.   BRITISH JOURNAL OF PHARMACOLOGY

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

(2010) K. Eechoute et al.   CLINICAL CANCER RESEARCH

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

(2009) Anne T. Nies et al.   HEPATOLOGY

Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge

(2009) Joo-Youn Cho et al.   JOURNAL OF LIPID RESEARCH

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy

(2008) Kunihiro Suzuki et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Imatinib for hepatocellular cancer – Focus on pharmacokinetic/pharmacodynamic modelling and liver function

(2008) G. Treiber et al.   CANCER LETTERS

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

(2008) Roos L. Oostendorp et al.   INVESTIGATIONAL NEW DRUGS

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

(2008) Ramesh K. Ramanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced Antidiabetic Effect of Metformin and Down-regulation of Hepatic Oct1 in Rats with Ethynylestradiol-Induced Cholestasis

(2008) Hyo-Eon Jin et al.   PHARMACEUTICAL RESEARCH

Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment

(2008) Stefan Sleijfer et al.   Nature clinical practice. Oncology

Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis

(2007) S Teng et al.   BRITISH JOURNAL OF PHARMACOLOGY